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abstractBACKGROUND: Coronary artery aneurysms (CAA) are a serious complication of Kawasaki disease.
Treatment with intravenous immunoglobulin (IVIg) within 10 days of fever onset reduces the
risk of CAA from 25% to ,5%. Corticosteroids and inﬂiximab are often used in high-risk
patients or those with CAA at diagnosis, but there are no data on their longer-term impact
on CAA.
METHODS: Retrospective multicenter study including children who had CAA with a z score $2.5
and ,10 at time of diagnosis and who received primary therapy with IVIg alone or in
combination with either corticosteroids or inﬂiximab within 10 days of onset of fever.
RESULTS: Of 121 children, with a median age of 2.8 (range 0.1–15.5) years, 30 (25%) received
primary therapy with corticosteroids and IVIg, 58 (48%) received primary therapy with
inﬂiximab and IVIg, and 33 (27%) received primary therapy with IVIg only. Median coronary z
scores at the time of diagnosis did not differ among treatment groups (P = .39). Primary
treatment intensiﬁcation with either corticosteroids or inﬂiximab were independent
protective factors against progression of coronary size on follow-up (coefﬁcient: 21.31 [95%
conﬁdence interval: 22.33 to 20.29]; coefﬁcient: 21.07 [95% conﬁdence interval: 21.95 to
20.19], respectively).
CONCLUSIONS: Among a high-risk group of patients with Kawasaki disease with CAA on baseline
echocardiography, those treated with corticosteroids or inﬂiximab in addition to IVIg had less
progression in CAA size compared with those treated with IVIg alone. Prospective randomized
trials are needed to determine the best adjunctive treatment of patients who present
with CAA.
WHAT’S KNOWN ON THIS SUBJECT: Treatment of
Kawasaki disease with intravenous immunoglobulin
within 10 days of fever reduces the risk of coronary
aneurysm from 25% to ,5%.
WHAT THIS STUDY ADDS: In high-risk patients with
Kawasaki disease who have coronary aneurysm on
baseline echocardiography, treatment intensiﬁcation with
corticosteroids or inﬂiximab is associated with less
progression of coronary aneurysm size compared with
treatment with intravenous immunoglobulin alone.
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Kawasaki disease (KD) is an acute
self-limited vasculitis that primarily
affects infants and young children.1
Coronary artery aneurysms (CAAs)
are a serious complication of KD,
placing patients at risk for coronary
thrombosis or stenosis, myocardial
infarction, and cardiac death.1–3
Intravenous immunoglobulin (IVIg) is
the mainstay of treatment and has
been shown to reduce the risk of CAA
from 25% to ,5%.4 Adjunctive
therapies beyond IVIg have been
sought to further reduce the
incidence of CAA.5–14 In the absence
of an evidence base, centers have
varied widely in their treatment
practices, including in the use of
corticosteroids, inﬂiximab, and other
adjunctive anti-inﬂammatory
medications for either intensiﬁcation
of primary therapy in high-risk
patients or rescue treatment of IVIg-
resistant patients.
In Japan, clinical risk scores have been
established and are used in clinical
practice to identify patients at high
risk of developing IVIg resistance and
CAA.15–17 In these patients, adjunctive
therapy with corticosteroids at time of
diagnosis has been shown to improve
coronary outcome.8 In the North
American population, the Japanese
clinical risk stratiﬁcation scores lack
both sensitivity and speciﬁcity for
identifying high-risk patients and thus
are not used in clinical practice.18,19
However, the coronary artery z score
at the time of diagnosis has proven to
be a strong predictor for future
adverse coronary outcome in North
America,20–23 providing a means of
selecting patients with KD at highest
risk for adverse coronary outcome.
In this retrospective multicenter
study, we evaluated the effect of
inﬂiximab and corticosteroids in
patients with KD and a coronary z
score $2.5 but ,10.0 at the time of
diagnosis. We hypothesized that
primary treatment with an adjunctive
anti-inﬂammatory therapy such as
corticosteroids or inﬂiximab together
with IVIg, compared with IVIg alone,
would improve coronary outcomes in
the high-risk population of children
whose coronary arteries were already
enlarged at the time of ﬁrst
presentation. Because 3 centers with
large KD populations in North
America differed in their treatment
practices, we were able to
retrospectively test our hypothesis.
METHODS
Population
This retrospective study included
children with a diagnosis of KD
between 2008 and 2017 treated at
Boston Children’s Hospital (Boston,
MA), Rady Children’s Hospital (San
Diego, CA), or Sainte-Justine’s
University Hospital Center (Montreal,
Canada) with CAA at the time of
diagnosis. We included all patients
with nongiant CAA on their initial
echocardiogram, deﬁned as a z score
$2.5 and ,10 in the right coronary
artery (RCA) or left anterior
descending coronary artery (LAD).
Exclusion criteria included the
following: (1) delayed IVIg treatment
(.10 days after fever onset) and (2)
coexisting congenital heart disease
(except for bicommissural aortic
valve without stenosis or
regurgitation), mitral valve prolapse,
and hemodynamically insigniﬁcant
ventricular septal defects.
Consistent, protocol-driven practice
variation across centers in the
treatment of patients with CAA at the
time of diagnosis allowed us to group
patients on the basis of their primary
treatment. Patients were classiﬁed
according to the primary therapy
received within the ﬁrst 48 hours
after diagnosis into the following
groups: (1) IVIg (2 g/kg) and
corticosteroids (center 1), (2) IVIg
(2 g/kg) and inﬂiximab (center 2), or
(3) IVIg (2 g/kg) alone (center 3).
Within each center, all patients
presenting with CAA received the
same treatment. All patients received
aspirin during the acute phase. High-
dose aspirin (80–100 mg/kg per day)
was initially used in all 3 centers;
center 2 switched to moderate-dose
aspirin (30–50 mg/kg per day) in
2013, and center 1 switched in 2016.
For patients who received
corticosteroids, dosing and duration
of treatment varied. Most commonly,
intravenous methylprednisolone at
2 mg/kg per day was started at the
time of diagnosis and continued for
48 hours or until the patient was
afebrile. Intravenous
methylprednisolone was then
changed to oral prednisolone at
2 mg/kg per day and tapered over
∼2 weeks at the time of outpatient
follow-up if inﬂammatory markers
remained low. Notably, during
a portion of the study period,
a second dose of IVIg was routinely
administered in patients with CAA in
addition to corticosteroids,
irrespective of clinical response to
ﬁrst IVIg treatment. For patients who
received inﬂiximab, the dose varied
over time with 5 mg/kg administered
until 2014 and 10 mg/kg
administered from 2014 to 2017.
Treatments were considered
secondary if given .48 hours after
KD diagnosis and given because of
persistent fever after primary therapy
(treatment resistance) or for
additional treatment of CAA.
Data Collection and Deﬁnitions
We reviewed medical records for
demographic characteristics, clinical
course, laboratory values, and
treatment received in the acute phase.
Children were classiﬁed as having
had complete or incomplete KD on
the basis of the 2017 American Heart
Association case deﬁnitions.1
Speciﬁcally, incomplete clinical
presentation was deﬁned as the
presence of fever and #3 clinical
criteria. We also classiﬁed patients
according to whether they received
treatment with corticosteroids,
inﬂiximab, or IVIg alone in the ﬁrst
48 hours after diagnosis. IVIg
resistance was deﬁned as persistent
or recrudescent fever (.38°C orally
or rectally) at least 36 hours after the
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end of the ﬁrst IVIg infusion.
Echocardiographic coronary
dimensions were reviewed at the
time of diagnosis and during the ﬁrst
year of follow-up after diagnosis of
KD. Coronary artery z scores were
calculated for the RCA and LAD by
using the Boston formula.22
Measurements of the left main
coronary artery were not used for
inclusion because of the signiﬁcant
normal variability described in
previous studies.1 Aneurysms were
considered small if z scores were
$2.5 to ,5, medium if z scores were
$5 to ,10, and large or giant if z
scores were $10 or .8 mm in
diameter.1 Regression of CAA was
deﬁned as a z score ,2 for all
coronary artery segments.
Outcomes
The primary outcome was change in
coronary z score (worst z score 2
baseline z score) for the RCA or the
LAD over the ﬁrst year of follow-up.
Secondary outcomes included
increase in coronary z score by more
than 1 SD unit, worst-ever coronary z
score, bilateral coronary involvement,
time to normalization of internal
lumen diameter (coronary z scores
,2 for both the RCA and LAD), and
resistance to initial treatment.
Statistical Analysis
Continuous variables were
summarized as mean 6 SD or median
(interquartile range [IQR], 25th–75th
percentile), and categorical variables
were summarized as frequencies and
percentages. Nonnormal distribution
of continuous variables was suggested
in the Shapiro-Wilk test. Comparison
of clinical characteristics across the 3
treatment groups was performed by
using the nonparametric median test.
The Fisher exact test was used for
comparison of categorical variables.
Median and logistic regressions were
used to examine the association
between primary treatment received
and increase in coronary z score
during follow-up, controlling for
potential confounder variables.
Nonparametric median regression was
used because of the signiﬁcantly
skewed distribution of the data, even
after log transformation. An increase
in coronary artery z score by more
than 1 SD unit during follow-up was
arbitrarily chosen as the cutoff value
for logistic regression. All analyses
were performed with SPSS Statistics
version 23 (IBM SPSS Statistics, IBM
Corporation, Chicago, IL). A 2-tailed P
value of,.05 was deemed statistically
signiﬁcant.
RESULTS
The study included 121 patients (88
boys, 73%), with a median age of 2.8
(range: 0.1–15.5) years; 26 (22%)
were younger than age 6 months at
time of KD diagnosis. Incomplete
clinical criteria were present in 44
(36%) of the children. Diagnosis was
made at a median of 6 (IQR: 4–8)
days from fever onset. All patients
received IVIg (2 g/kg) at the time of
diagnosis. Primary therapy was
corticosteroids plus IVIg in 30
patients (25%), inﬂiximab plus IVIg
in 58 patients (48%), and IVIg alone
in 33 patients (27%) (Table 1). There
was no signiﬁcant difference in
coronary artery z score at the time of
diagnosis among the groups
(Table 2). At the time of diagnosis, 42
(35%) patients had bilateral coronary
involvement with no difference
between treatment groups.
Overall, secondary treatment was
administered in 50 (41%) patients,
for the indication of persistent fever
after primary treatment in 15 (12%)
patients and for coronary
abnormalities in 35 (29%) patients.
Additional therapies consisted of
a second dose of IVIg in 38 (31%)
patients, corticosteroids in 12
patients (10%), cyclosporine in 10
patients (8%), anakinra in 6 patients
(5%), and cyclophosphamide in 2
patients (2%). Patients who were
initially treated with IVIg only or IVIg
and inﬂiximab were more likely to
require additional therapies because
of persistent fever, compared with
those who received IVIg and
corticosteroids (7 [21%] vs 8 [14%]
vs 0 [0%], P = .03). Additional
treatments for coronary
abnormalities were administered
more frequently in patients who
TABLE 1 Patients’ Characteristics Stratiﬁed by Initial Therapy Received
Baseline Characteristics IVIg Only, n = 33 IVIg and Inﬂiximab, n = 58 IVIg and Corticosteroids,
n = 30
Pa
Age in y, median (IQR) 2.0 (1.2 to 5.6) 1.1 (0.5 to 3.0) 2.6 (0.9 to 4.5) .04
Infant ,6 mo, n (%) 9 (27) 16 (28) 5 (17) .29
Boy, n (%) 19 (58) 44 (77) 25 (83) ,.001
Length of fever in d, median (IQR) 6 (4 to 7) 5 (3 to 6) 6 (4 to 7) .28
Complete clinical criteria, n (%) 20 (61) 46 (79) 11 (37) ,.001
Persistence of fever after IVIg treatment,
n (%)
7 (21) 8 (14) 0 (0) .02
Additional therapies, n (%) 14 (42) 19 (33) 17 (57) .10
Second dose of IVIgb, n (%) 11 (33) 10 (17) 17 (57) .001
Other immunosuppressive therapies, n
(%)
11 (33) 12 (21) 3 (10) .084
a Nonparametric test for median for continuous values; Fisher exact test for qualitative values.
b A second dose of IVIg was routinely administered in patients with CAAs at the center using corticosteroids, irrespective of clinical response to ﬁrst IVIg treatment.
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initially received IVIg and
corticosteroids, followed by those
who received IVIg only and IVIg and
inﬂiximab (17 [57%] vs 7 [21%] vs
11 [19%], P = .001).
During follow-up, the maximal
coronary artery z score increased by
a median of 0.4 SD units (IQR: 0–1.8)
(Fig 1). Primary treatment
intensiﬁcation with corticosteroids or
inﬂiximab, compared with IVIg alone,
was associated with less progression
in coronary artery size on follow-up
(unadjusted P = .004, P = .001,
respectively). Use of corticosteroids
or inﬂiximab remained independently
associated with less progression in
coronary size on multivariable
analysis (Table 3). A higher
proportion of patients who received
IVIg only had an increase in coronary
artery z score by more than 1 SD unit,
compared with patients whose
primary therapy included inﬂiximab
or corticosteroids (19 [58%] vs 14
[24%] vs 7 [23%] patients, P = .003;
Table 4). In a multivariable logistic
regression analysis, primary
treatment with corticosteroids or
inﬂiximab was associated with
a lower likelihood of increase in
coronary artery z score by .1
(P = .02, P = .002, respectively;
Table 4).
The worst-ever coronary artery z score
was similar between the 3 treatment
groups (3.5 [IQR: 2.9–6.3] for IVIg only
versus 4.0 [IQR: 3.0–5.0] for IVIg and
inﬂiximab versus 3.6 [IQR: 3.2–5.3] for
IVIg and corticosteroids, P = .85). A
similar proportion of patients in each
treatment group developed giant
aneurysms during follow-up (4 [12%]
patients who received IVIg only versus
5 [9%] patients who received IVIg and
inﬂiximab versus 1 [3%] patient who
received IVIg and corticosteroids,
P = .49). CAA regressed to normal
internal lumen diameter (z score,2.0)
during the ﬁrst year of follow-up in 91
(75%) patients, with no difference
among groups in regression rate (26
[79%] vs 43 [74%] vs 24 [80%] for
patients who received IVIg only, IVIg
and inﬂiximab, or IVIg and
corticosteroids, respectively, P = .85).
DISCUSSION
In this retrospective series, adjunctive
primary treatment with
TABLE 2 Coronary Artery Outcome Stratiﬁed by Treatment Group
Coronary Outcome IVIg Only, n = 33 IVIg and Inﬂiximab, n = 58 IVIg and Corticosteroids,
n = 30
Pa
Baseline, median (IQR)
RCA z score 2.8 (1.2 to 3.5) 2.6 (1.6 to 3.8) 2.6 (1.6 to 3.3) .46
LAD z score 2.5 (0.9 to 3.5) 3.1 (2.7 to 3.9) 3.2 (2.8 to 4.4) .12
Maximum coronary z score 3.2 (2.8 to 4.2) 3.6 (2.9 to 4.3) 3.5 (3.0 to 4.5) .39
At 12 mo postonset
Maximum coronary z score,
median (IQR)
0.6 (20.3 to 1.5) 1.3 (0.6 to 2.2) 1.0 (0.5 to 1.8) .21
Regression aneurysmb, n (%) 26 (79) 43 (74) 24 (80) .82
Maximum coronary z score within
ﬁrst 12 mo, median (IQR)
3.5 (2.9 to 6.3) 4.0 (3.0 to 5.0) 3.6 (3.2 to 5.3) .85
Giant aneurysms, n (%) 4 (12) 5 (9) 1 (3) .49
Increase in coronary dimensions
during follow-up
Maximum ↑ in z scorec, median
(IQR)
1.5 (0.0 to 3.2) 0.3 (0.0 to 1.0) 0.3 (0.0 to 1.0) .057
↑ in z score .1 SD unit, n (%) 19 (58) 14 (24) 7 (23) .003
↑ in z score .2 SD unit, n (%) 8 (24) 6 (10) 5 (17) .058
↑, increase.
a Nonparametric test for median for continuous values; Fisher exact test for qualitative values.
b Regression deﬁned as a z score ,2 for all coronary artery segments.
c Worst coronary artery z score 2 baseline coronary artery z score.
FIGURE 1
A, Increase in coronary artery z score during the ﬁrst year of follow-up (worst coronary artery z
score 2 baseline coronary artery z score) based on treatment received. B, Percentage of patients
with increase in coronary artery z score by more than 1 SD unit during follow-up based on initial
treatment received. CA, coronary artery.
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corticosteroids or inﬂiximab may be
beneﬁcial in preventing CAA
progression. Patients who received
primary treatment intensiﬁcation
with either corticosteroids or
inﬂiximab had less increase in
coronary artery z score during follow-
up compared with those who
received IVIg alone. However, there
was no signiﬁcant difference in
maximal coronary artery z score or
the CAA regression rate. With these
ﬁndings, it is suggested that primary
adjunctive treatment with
corticosteroids or inﬂiximab may be
beneﬁcial in patients with CAA at the
time of diagnosis.
The 2017 American Heart Association
guidelines recommend primary
adjunctive therapy for patients
considered to be at high risk for CAA.
However, the deﬁnition of high risk in
the non-Japanese population is not
standardized, and the optimal
treatment of primary adjunctive
therapy is not well established. In
a study by Kobayashi et al,8
researchers provide convincing
evidence for the use of
corticosteroids in Japanese patients
who are high risk for IVIg resistance
by clinical scoring systems, but there
are limitations in generalizability
because clinical risk scores are
problematic outside of Japan and the
study excluded patients with CAA at
presentation (based on Japanese
Ministry of Health criteria). The
current study is the ﬁrst to evaluate
primary treatment intensiﬁcation
with corticosteroids in patients
presenting with CAA and, similar to
the study by Kobayashi et al,8 shows
corticosteroids to be beneﬁcial for
coronary arteries and clinical
outcomes. The data for inﬂiximab in
children presenting with CAA are
limited to a single retrospective,
single-site experience14 and were
used to show that inﬂiximab as initial
therapy reduced the need for
additional treatments; however, there
was no signiﬁcant difference in length
of stay, improvement in coronary z
scores at 2 to 6 weeks, or rate of
decrease in C-reactive protein.
Although it is suggested in our
observational study that adjunctive
primary therapy with corticosteroids
or inﬂiximab may improve coronary
outcomes in those who present with
a coronary z score $2.5, prospective,
randomized studies are needed to
identify optimal therapy in this
patient population.
In addition to improved coronary
outcomes, the rate of primary
treatment resistance was lower in
patients who received corticosteroids
compared with those who received
inﬂiximab or IVIg only. Duration of
fever and resistance to IVIg treatment
are well-established risk factors for
TABLE 3 Multivariable Median Linear Regression for Increase in Coronary Artery Z Score During Follow-up
Predictors Coefﬁcients 95% CI P
Boy 0.01 20.81 to 0.83 .98
Age at time of diagnosis in y 0.07 20.04 to 0.18 .23
Length of fever in d at time of
diagnosis
20.03 20.20 to 0.15 .75
Corticosteroids 21.31 22.33 to 20.29 .012
Inﬂiximab 21.07 21.95 to 20.19 .018
Second dose of IVIg 0.27 20.55 to 1.08 .52
Other immunosuppressive therapies 20.31 21.22 to 0.61 .51
Baseline coronary z score 0.43 0.20 to 0.66] ,.001
CI, conﬁdence interval.
TABLE 4 Univariate and Multivariable Logistic Regression for Increase in Coronary Artery Z Score During Follow-up
Predictors Univariate Multivariable
No Increase in CA Z Scores .1, n = 81 Increase in CA Z Scores
.1, n = 40
P OR 95% CI P
Male, n (%) 59 (73) 29 (73) .23 1.72 0.60 to 4.88 .31
Age at time of diagnosis in y, median (IQR) 1.5 (0.6 to 3.4) 2.2 (0.7 to 4.1) .16 1.08 0.94 to 1.24 .30
Length of fever in d at time of diagnosis, median (IQR) 6 (4.5 to 7) 7 (4 to 8) .37 1.04 0.83 to 1.30 .73
Primary treatment, n (%) — — .003 — — —
IVIg only, n = 33 14 (42) 19 (58) — 1 — —
IVIg and corticosteroids, n = 30 23 (77) 7 (23) — 0.21 0.06 to 0.77 .02
IVIg and inﬂiximab, n = 58 44 (76) 14 (24) — 0.17 0.06 to 0.51 .002
IVIg resistance, n (%) 10 (12) 6 (15) .78 4.31 0.70 to 26.37 .11
Second dose of IVIg, n (%) 24 (30) 14 (35) .68 0.63 0.18 to 2.26 .48
Other immunosuppressive therapies, n (%) 15 (19) 11 (28) .35 0.98 0.32 to 3.01 .97
Baseline bilateral CAAs, n (%) 26 (32) 16 (40) .42 1.90 0.62 to 5.81 .26
Baseline coronary z score, median (IQR) 3.4 (2.9, 4.2) 3.5 (2.9, 4.6) .90 1.25 0.91 to 1.71 .17
CA, coronary artery; CI, conﬁdence interval; OR, odds ratio; —, not applicable.
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the development of CAA.1 In previous
studies, it has been shown that
corticosteroids at the time of KD
diagnosis reduce the duration of fever
and initial treatment failure rate
compared with IVIg alone.8,24,25
Corticosteroids are effective in
a broad range of vasculitides and
other inﬂammatory conditions.
Corticosteroids suppress fever and
inﬂammation through inhibition of
prostaglandins and other
inﬂammatory cytokines.26 Although
evidence is provided in the current
study that corticosteroids decrease
primary treatment failure, questions
remain whether corticosteroids are
only masking fever or fully
suppressing inﬂammation. Inﬂiximab,
a monoclonal antibody, is a more
selective anti-inﬂammatory treatment
that works by blocking tumor necrosis
factor a. The proinﬂammatory
cytokine tumor necrosis factor a has
been shown to be elevated in patients
with KD, with the highest levels
observed in patients with CAA.27 In
previous studies, primary adjunctive
treatment with inﬂiximab reduced
duration of fever but was not
associated with a decreased risk of
treatment resistance.13 Further
randomized controlled trials are
needed to determine if primary
adjunctive therapy with
corticosteroids leads to a lower rate of
primary treatment resistance and if
this results in improved clinical and
coronary outcomes.
This study should be interpreted in
light of its limitations. In this
retrospective review, treatment
administered was based on patients’
characteristics and local center
practice. The use of adjunctive
therapies (second IVIg dose and other
anti-inﬂammatory agents) was
inconsistent among centers, with
different indications for
intensiﬁcation of treatment based on
coronary status. The center using
corticosteroids routinely
administered a second IVIg dose in
patients with CAA at the time of
diagnosis, irrespective of response to
primary therapy. Although we were
able to account for some of the
variation in practice across centers in
a multivariate model, there may have
been other confounders that we could
not account for. The majority of
patients in this study had small CAA
at diagnosis (102 patients, 86%).
Compared with patients with larger
CAA, those with small aneurysms are
considerably more likely to have
aneurysm regression regardless of
treatment.23 Thus, we had limited
ability to identify the effects of
treatment on progression to giant
CAA and regression to normal
internal lumen diameter. The
treatment cohorts were relatively
small, which limits our ability to
perform subgroup analysis and the
statistical power to show a signiﬁcant
difference, particularly in progression
to giant CAA. Moreover,
echocardiograms were interpreted
in each center, and there was
no centralized review of
echocardiogram and coronary
artery measurements.
CONCLUSIONS
In this series, adjunctive primary
treatment with either corticosteroids or
inﬂiximab was superior to IVIg alone in
preventing CAA progression. Patients
who received primary treatment
intensiﬁcation with corticosteroids or
inﬂiximab had less progression of
coronary dilation on follow-up.
However, maximal coronary artery z
score and the rate of CAA regression
were similar among groups. Our data
suggest that adjunctive treatment at
the time of diagnosis may be beneﬁcial
in patients with CAA. Future
adequately powered, prospective
randomized trials are needed to
determine the best adjunctive
treatment of patients with KD who
present with coronary changes.
ABBREVIATIONS
CAA: coronary artery aneurysm
IQR: interquartile range
IVIg: intravenous immunoglobulin
KD: Kawasaki disease
LAD: left anterior descending
coronary artery
RCA: right coronary artery
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